Research ExplorerPublicationsImpact of disease burden on clinical outcomes of AML patient...

Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Standard

Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. / Abou Dalle, Iman; Labopin, Myriam; Kröger, Nicolaus; Schroeder, Thomas; Finke, Jürgen; Stelljes, Matthias; Neubauer, Andreas; Blaise, Didier; Yakoub-Agha, Ibrahim; Salmenniemi, Urpu; Forcade, Edouard; Itäla-Remes, Maija; Dreger, Peter; Bug, Gesine; Passweg, Jakob; Heuser, Michael; Choi, Goda; Brissot, Eolia; Giebel, Sebastian; Nagler, Arnon; Ciceri, Fabio; Bazarbachi, Ali; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 58, No. 7, 07.2023, p. 784-790.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Abou Dalle, I, Labopin, M, Kröger, N, Schroeder, T, Finke, J, Stelljes, M, Neubauer, A, Blaise, D, Yakoub-Agha, I, Salmenniemi, U, Forcade, E, Itäla-Remes, M, Dreger, P, Bug, G, Passweg, J, Heuser, M, Choi, G, Brissot, E, Giebel, S, Nagler, A, Ciceri, F, Bazarbachi, A & Mohty, M 2023, 'Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation', BONE MARROW TRANSPL, vol. 58, no. 7, pp. 784-790. https://doi.org/10.1038/s41409-023-01961-1

APA

Abou Dalle, I., Labopin, M., Kröger, N., Schroeder, T., Finke, J., Stelljes, M., Neubauer, A., Blaise, D., Yakoub-Agha, I., Salmenniemi, U., Forcade, E., Itäla-Remes, M., Dreger, P., Bug, G., Passweg, J., Heuser, M., Choi, G., Brissot, E., Giebel, S., ... Mohty, M. (2023). Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. BONE MARROW TRANSPL, 58(7), 784-790. https://doi.org/10.1038/s41409-023-01961-1

Vancouver

Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. BONE MARROW TRANSPL. 2023 Jul;58(7):784-790. https://doi.org/10.1038/s41409-023-01961-1

Bibtex

@article{c9384bf5f6654528916a9db0e720d292,
title = "Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation",
abstract = "Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.",
keywords = "Adult, Humans, Bone Marrow, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation/adverse effects, Leukemia, Myeloid, Acute, Recurrence, Neoplasm, Residual, Cost of Illness, Retrospective Studies",
author = "{Abou Dalle}, Iman and Myriam Labopin and Nicolaus Kr{\"o}ger and Thomas Schroeder and J{\"u}rgen Finke and Matthias Stelljes and Andreas Neubauer and Didier Blaise and Ibrahim Yakoub-Agha and Urpu Salmenniemi and Edouard Forcade and Maija It{\"a}la-Remes and Peter Dreger and Gesine Bug and Jakob Passweg and Michael Heuser and Goda Choi and Eolia Brissot and Sebastian Giebel and Arnon Nagler and Fabio Ciceri and Ali Bazarbachi and Mohamad Mohty",
note = "{\textcopyright} 2023. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2023",
month = jul,
doi = "10.1038/s41409-023-01961-1",
language = "English",
volume = "58",
pages = "784--790",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

AU - Abou Dalle, Iman

AU - Labopin, Myriam

AU - Kröger, Nicolaus

AU - Schroeder, Thomas

AU - Finke, Jürgen

AU - Stelljes, Matthias

AU - Neubauer, Andreas

AU - Blaise, Didier

AU - Yakoub-Agha, Ibrahim

AU - Salmenniemi, Urpu

AU - Forcade, Edouard

AU - Itäla-Remes, Maija

AU - Dreger, Peter

AU - Bug, Gesine

AU - Passweg, Jakob

AU - Heuser, Michael

AU - Choi, Goda

AU - Brissot, Eolia

AU - Giebel, Sebastian

AU - Nagler, Arnon

AU - Ciceri, Fabio

AU - Bazarbachi, Ali

AU - Mohty, Mohamad

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2023/7

Y1 - 2023/7

N2 - Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.

AB - Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.

KW - Adult

KW - Humans

KW - Bone Marrow

KW - Transplantation, Homologous

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Leukemia, Myeloid, Acute

KW - Recurrence

KW - Neoplasm, Residual

KW - Cost of Illness

KW - Retrospective Studies

U2 - 10.1038/s41409-023-01961-1

DO - 10.1038/s41409-023-01961-1

M3 - SCORING: Journal article

C2 - 37041215

VL - 58

SP - 784

EP - 790

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -